Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease

World Journal of Gastroenterology

Volumn 21, Issue 4, 2015, Pages 1099-1107

  Qiu, Long Xin ^a,b   Chen, Tong ^a,b  

^a LONGYAN UNIVERSITY   (China)

^b Fujian Key Laboratory of Preventive Veterinary Medicine and Biotechnology   (China)

Author keywords

Aldose reductase; Cytochrome P450 2E1; Endotoxin; Fatty liver disease; Fructose; Isoflavones; Peroxisome proliferator activated receptor

Indexed keywords

ALDEHYDE REDUCTASE; CYTOCHROME P450 2E1; ENDOTOXIN; ISOFLAVONE DERIVATIVE; LIVER PROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; POLYOL; AUTACOID; CYTOKINE; PROTECTIVE AGENT;

ALCOHOL LIVER DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; FATTY ACID OXIDATION; GLUCOSE INTAKE; HUMAN; INTESTINE FLORA; LIPID STORAGE; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; ANIMAL; BACTERIUM; CELL PROTECTION; DRUG EFFECTS; ENERGY METABOLISM; IMMUNOLOGY; INTESTINE; LIVER; LIVER DISEASES, ALCOHOLIC; METABOLISM; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOGENICITY; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; BACTERIA; CYTOKINES; CYTOPROTECTION; ENERGY METABOLISM; HUMANS; INFLAMMATION MEDIATORS; INTESTINES; ISOFLAVONES; LIVER; LIVER DISEASES, ALCOHOLIC; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PROTECTIVE AGENTS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84921712206     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i4.1099     Document Type: Review

References (86)

1. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011; 48: 97-113 [PMID: 21875310 DOI: 10.3109/10408363.2011.596521]
2. Cao HX, Fan JG. Editorial: Fatty liver disease: a growing public health problem worldwide. J Dig Dis 2011; 12: 1-2 [PMID: 21091929 DOI: 10.1111/j.1751-2980.2010.00467.x]
3. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 2011; 13: 692-702 [PMID: 21449949 DOI: 10.1111/j.1463-1326.2011.01403.x]
4. Kim MH, Kang KS. Isoflavones as a smart curer for non-alcoholic fatty liver disease and pathological adiposity via ChREBP and Wnt signaling. Prev Med 2012; 54 Suppl: S57-S63 [PMID: 22227283 DOI: 10.1016/j.ypmed.2011.12.018]
5. Lanaspa MA, Ishimoto T, Li N, Cicerchi C, Orlicky DJ, Ruzycki P, Rivard C, Inaba S, Roncal-Jimenez CA, Bales ES, Diggle CP, Asipu A, Petrash JM, Kosugi T, Maruyama S, Sanchez-Lozada LG, McManaman JL, Bonthron DT, Sautin YY, Johnson RJ. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun 2013; 4: 2434 [PMID: 24022321 DOI: 10.1038/ncomms3434]
6. Qiu L, Lin J, Xu F, Gao Y, Zhang C, Liu Y, Luo Y, Yang JY. Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice. Exp Diabetes Res 2012; 2012: 789730 [PMID: 22110479 DOI: 10.1155/2012/789730]
7. Qiu L, Lin J, Ying M, Chen W, Yang J, Deng T, Chen J, Shi D, Yang JY. Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis. PLoS One 2013; 8: e73591 [PMID: 24066058 DOI: 10.1371/journal.pone.0073591]
8. Veeresham C, Rama Rao A, Asres K. Aldose reductase inhibitors of plant origin. Phytother Res 2014; 28: 317-333 [PMID: 23674239 DOI: 10.1002/ptr.5000]
9. Park CH, Lim SS, Lee DU. Structure-activity relationships of components from the roots of pueraria thunbergiana having aldose reductase inhibitory and antioxidative activity. Bull Korean Chem Soc 2007; 28: 493-495
10. Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med 2011; 11: 176-178 [PMID: 21526706 DOI: 10.7861/clinmedicine.11-2-176]
11. Gramenzi A, Caputo F, Biselli M, Kuria F, Loggi E, Andreone P, Bernardi M. Review article: alcoholic liver disease-pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006; 24: 1151-1161 [PMID: 17014574 DOI: 10.1111/j.1365-2036.2006.03110. x]
12. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-644 [PMID: 19575462 DOI: 10.1002/hep.23009]
13. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 2006; 44: 253-261 [PMID: 16364488 DOI: 10.1016/j.jhep.2005.11.030]
14. Voican CS, Perlemuter G. Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis. J Hepatol 2011; 54: 388-391 [PMID: 21112115 DOI: 10.1016/j.jhep.2010.07.054]
15. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103: 1036-1042 [PMID: 18177455 DOI: 10.1111/j.1572-0241.2007.01709.x]
16. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in nonalcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-1305 [PMID: 21514287 DOI: 10.1016/j.cca.2011.04.013]
17. Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol 2014; 29: 1139-1148 [PMID: 24547986 DOI: 10.1111/jgh.12556]
18. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
19. Li YY. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 6546-6551 [PMID: 23236228 DOI: 10.3748/wjg.v18.i45.6546]
20. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102 DOI: 10.1016/ S0016-5085(98)70599-2]
21. Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: a tale of "second hit". World J Gastroenterol 2013; 19: 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158]
22. Barnes S. Evolution of the health benefits of soy isoflavones. Proc Soc Exp Biol Med 1998; 217: 386-392 [PMID: 9492352 DOI: 10.3181/00379727-217-44249]
23. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999; 129: 758S-767S [PMID: 10082786]
24. Lee YM, Choi JS, Kim MH, Jung MH, Lee YS, Song J. Effects of dietary genistein on hepatic lipid metabolism and mitochondrial function in mice fed high-fat diets. Nutrition 2006; 22: 956-964 [PMID: 16814985]
25. Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2007; 22: 2009-2014 [PMID: 17914984 DOI: 10.1111/j.1440-1746.2006.04681.x]
26. Ustundag B, Bahcecioglu IH, Sahin K, Duzgun S, Koca S, Gulcu F, Ozercan IH. Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model. Dig Dis Sci 2007; 52: 2006-2014 [PMID: 17420940 DOI: 10.1007/s10620-006-9251-9]
27. Mohamed Salih S, Nallasamy P, Muniyandi P, Periyasami V, Carani Venkatraman A. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J Diabetes 2009; 1: 278-287 [PMID: 20923528 DOI: 10.1111/j.1753-0407.2009.00045.x]
28. Kim MH, Kang KS, Lee YS. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br J Nutr 2010; 104: 1333-1342 [PMID: 20687969 DOI: 10.1017/S0007114510002266]
29. Ji G, Yang Q, Hao J, Guo L, Chen X, Hu J, Leng L, Jiang Z. Antiinflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol 2011; 11: 762-768 [PMID: 21320636 DOI: 10.1016/j.intimp.2011.01.036]
30. Huang Q, Huang R, Zhang S, Lin J, Wei L, He M, Zhuo L, Lin X. Protective effect of genistein isolated from Hydrocotyle sibthorpioides on hepatic injury and fibrosis induced by chronic alcohol in rats. Toxicol Lett 2013; 217: 102-110 [PMID: 23274713 DOI: 10.1016/j.toxlet.2012.12.014]
31. Kwon YH, Jeon S, Park YJ. Inhibitory effect of genistein on nonalcoholic fatty liver disease development in ApoE-/-mice fed a high-fat diet. FASEB J 2013; 27: 862
32. Kim MH, Park JS, Jung JW, Byun KW, Kang KS, Lee YS. Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int J Obes (Lond) 2011; 35: 1019-1030 [PMID: 21157426 DOI: 10.1038/ijo.2010.256]
33. Crespillo A, Alonso M, Vida M, Pavón FJ, Serrano A, Rivera P, Romero-Zerbo Y, Fernández-Llebrez P, Martínez A, Pérez-Valero V, Bermúdez-Silva FJ, Suárez J, de Fonseca FR. Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. Br J Pharmacol 2011; 164: 1899-1915 [PMID: 21557739 DOI: 10.1111/j.1476-5381.2011.01477.x]
34. Zheng P, Ji G, Ma Z, Liu T, Xin L, Wu H, Liang X, Liu J. Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chin Med 2009; 37: 69-83 [PMID: 19222113 DOI: 10.1142/S0192415X09006692]
35. Zhao M, Du YQ, Yuan L, Wang NN. Protective effect of puerarin on acute alcoholic liver injury. Am J Chin Med 2010; 38: 241-249 [PMID: 20387222 DOI: 10.1142/S0192415X10007816]
36. Xiong Y, Yang Y, Yang J, Chai H, Li Y, Yang J, Jia Z, Wang Z. Tectoridin, an isoflavone glycoside from the flower of Pueraria lobata, prevents acute ethanol-induced liver steatosis in mice. Toxicology 2010; 276: 64-72 [PMID: 20637825 DOI: 10.1016/j.tox.2010.07.007]
37. Noh BK, Lee JK, Jun HJ, Lee JH, Jia Y, Hoang MH, Kim JW, Park KH, Lee SJ. Restoration of autophagy by puerarin in ethanoltreated hepatocytes via the activation of AMP-activated protein kinase. Biochem Biophys Res Commun 2011; 414: 361-366 [PMID: 21964292 DOI: 10.1016/j.bbrc.2011.09.077]
38. Kamiya T, Sameshima-Kamiya M, Nagamine R, Tsubata M, Ikeguchi M, Takagaki K, Shimada T, Aburada M. The crude extract from puerariae flower exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice. Evid Based Complement Alternat Med 2012; 2012: 272710 [PMID: 22685484 DOI: 10.1155/2012/272710]
39. Peng JH, Cui T, Huang F, Chen L, Zhao Y, Xu L, Xu LL, Feng Q, Hu YY. Puerarin ameliorates experimental alcoholic liver injury by inhibition of endotoxin gut leakage, Kupffer cell activation, and endotoxin receptors expression. J Pharmacol Exp Ther 2013; 344: 646-654 [PMID: 23277536 DOI: 10.1124/jpet.112.201137]
40. Qiu L, Chen T, Zhong F, Hong Y, Chen L, Ye H. Red clover extract exerts antidiabetic and hypolipidemic effects in db/db mice. Exp Ther Med 2012; 4: 699-704 [PMID: 23170129 DOI: 10.3892/etm.2012.658]
41. Chen T, Zhong FJ, Hong YM, Su WJ, Zhuang LL, Qiu LX. Effect of Trifolium pratense extract on methionine-cholinedeficient diet-induced steatohepatitis in C57BL/6 mice. Chin J Nat Med 2014; 12: 194-198 [PMID: 24702805 DOI: 10.1016/S1875-5364(14)60032-7]
42. Andersen C, Schjoldager JG, Tortzen CG, Vegge A, Hufeldt MR, Skaanild MT, Vogensen FK, Kristiansen K, Hansen AK, Nielsen J. 2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice. Biomed Res Int 2013; 2013: 926942 [PMID: 23738334 DOI: 10.1155/2013/926942]
43. Breikaa RM, Algandaby MM, El-Demerdash E, Abdel-Naim AB. Multimechanistic antifibrotic effect of biochanin a in rats: implications of proinflammatory and profibrogenic mediators. PLoS One 2013; 8: e69276 [PMID: 23874933 DOI: 10.1371/journal.pone.0069276]
44. Hers HG. [Aldose reductase]. Biochim Biophys Acta 1960; 37: 120-126 [PMID: 14401390]
45. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs 1999; 8: 2095-2119 [PMID: 11139842]
46. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21-33 [PMID: 9549756]
47. O'connor T, Ireland LS, Harrison DJ, Hayes JD. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldoketo reductase AKR1 family members. Biochem J 1999; 343 Pt 2: 487-504 [PMID: 10510318 DOI: 10.1042/0264-6021:]
48. Brown KE, Broadhurst KA, Mathahs MM, Kladney RD, Fimmel CJ, Srivastava SK, Brunt EM. Immunodetection of aldose reductase in normal and diseased human liver. Histol Histopathol 2005; 20: 429-436 [PMID: 15736047]
49. Hsieh PC, Huang GJ, Ho YL, Lin YH, Huang SS, Chiang YC, Tseng MC, Chang YS. Activities of antioxidants, α-Glucosidase inhibitors and aldose reductase inhibitors of the aqueous extracts of four Flemingia species in Taiwan. Bot Stud 2010; 51: 293-302
50. Choi SW, Yang JS, Jung EA, Choi HJ, Lee HS, Shin CS, Kim DS, Hur NY, Baik MY. Isolation and structural determination of aldose reductase inhibitor from Korean fermented soybean paste. Food Sci Biotechnol 2005; 14: 344-349
51. Jung SH, Lee YS, Lee S, Lim SS, Kim YS, Shin KH. Isoflavonoids from the rhizomes of Belamcanda chinensis and their effects on aldose reductase and sorbitol accumulation in streptozotocin induced diabetic rat tissues. Arch Pharm Res 2002; 25: 306-312 [PMID: 12135102 DOI: 10.1007/BF02976631]
52. Madeswaran A, Umamaheswari M, Asokkumar K, Sivashanmugam T, Subhadradevi V, Jagannath P. In silico docking studies of aldose reductase inhibitory activity of commercially available flavonoids. Bangladesh J Pharmacol 2012; 7: 266-271 [DOI: 10.3329/bjp.v7i4.12314]
53. Ae Park S, Choi MS, Cho SY, Seo JS, Jung UJ, Kim MJ, Sung MK, Park YB, Lee MK. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJdb/ db mice. Life Sci 2006; 79: 1207-1213 [PMID: 16647724 DOI: 10.1016/j.lfs.2006.03.022]
54. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005; 51: 85-94 [PMID: 15629253 DOI: 10.1016/j.phrs.2004.07.012]
55. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 2011; 141: 603-610 [PMID: 21346097 DOI: 10.3945/jn.110.135210]
56. Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 1998; 102: 1083-1091 [PMID: 9739042 DOI: 10.1172/JCI3949]
57. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39: 1286-1296 [PMID: 15122757 DOI: 10.1002/hep.20170]
58. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-132 [PMID: 12829994 DOI: 10.1053/jhep.2003.50307]
59. Kong L, Ren W, Li W, Zhao S, Mi H, Wang R, Zhang Y, Wu W, Nan Y, Yu J. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice. Lipids Health Dis 2011; 10: 246 [PMID: 22208561 DOI: 10.1186/1476-511X-10-246]
60. Mueller M, Hobiger S, Jungbauer A. Red clover extract: a source for substances that activate peroxisome proliferatoractivated receptor alpha and ameliorate the cytokine secretion profile of lipopolysaccharide-stimulated macrophages. Menopause 2010; 17: 379-387 [PMID: 20142789 DOI: 10.1097/gme.0b013e3181c94617]
61. Qiu L, Lin B, Lin Z, Lin Y, Lin M, Yang X. Biochanin A ameliorates the cytokine secretion profile of lipopolysaccharidestimulated macrophages by a PPARγ-dependent pathway. Mol Med Rep 2012; 5: 217-222 [PMID: 21946955 DOI: 10.3892/mmr.2011.599]
62. Qiu L, Wu X, Chau JF, Szeto IY, Tam WY, Guo Z, Chung SK, Oates PJ, Chung SS, Yang JY. Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis. J Biol Chem 2008; 283: 17175-17183 [PMID: 18445591 DOI: 10.1074/jbc.M801791200]
63. Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and-independent mechanisms. Physiol Genomics 2006; 26: 8-14 [PMID: 16507786 DOI: 10.1152/physiolgenomics.00155.2005]
64. Iqbal MJ, Yaegashi S, Ahsan R, Lightfoot DA, Banz WJ. Differentially abundant mRNAs in rat liver in response to diets containing soy protein isolate. Physiol Genomics 2002; 11: 219-226 [PMID: 12388795 DOI: 10.1152/physiolgenomics.00078.2002]
65. Badger TM, Ronis MJ, Wolff G, Stanley S, Ferguson M, Shankar K, Simpson P, Jo CH. Soy protein isolate reduces hepatosteatosis in yellow Avy/a mice without altering coat color phenotype. Exp Biol Med (Maywood) 2008; 233: 1242-1254 [PMID: 18791133 DOI: 10.3181/0802-RM-60]
66. Rimbach G, De Pascual-Teresa S, Ewins BA, Matsugo S, Uchida Y, Minihane AM, Turner R, VafeiAdou K, Weinberg PD. Antioxidant and free radical scavenging activity of isoflavone metabolites. Xenobiotica 2003; 33: 913-925 [PMID: 14514441]
67. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 1997; 26: 63-70 [PMID: 9018473]
68. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013; 58: 395-398 [PMID: 22940046 DOI: 10.1016/j.jhep.2012.08.018]
69. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075 [PMID: 10772651 DOI: 10.1172/JCI8814]
70. Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 2008; 44: 723-738 [PMID: 18078827 DOI: 10.1016/j.freeradbiomed.2007.11.004]
71. Nanji AA, Zhao S, Sadrzadeh SM, Dannenberg AJ, Tahan SR, Waxman DJ. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats. Alcohol Clin Exp Res 1994; 18: 1280-1285 [PMID: 7847620 DOI: 10.1111/j.1530-0277.1994.tb00119.x]
72. Robin MA, Sauvage I, Grandperret T, Descatoire V, Pessayre D, Fromenty B. Ethanol increases mitochondrial cytochrome P450 2E1 in mouse liver and rat hepatocytes. FEBS Lett 2005; 579: 6895-6902 [PMID: 16337197 DOI: 10.1016/j.febslet.2005.11.029]
73. Bardag-Gorce F, Yuan QX, Li J, French BA, Fang C, Ingelman-Sundberg M, French SW. The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. Biochem Biophys Res Commun 2000; 279: 23-29 [PMID: 11112412 DOI: 10.1006/bbrc.2000.3889]
74. Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int 2007; 27: 764-771 [PMID: 17617119 DOI: 10.1111/j.1478-3231.2007.01524.x]
75. Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, Smok G, Videla LA. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 2006; 34: 57-63 [PMID: 16321567]
76. Kathirvel E, Morgan K, French SW, Morgan TR. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009; 21: 973-983 [PMID: 19307976 DOI: 10.1097/MEG.0b013e328328f461]
77. Mrozikiewicz PM, Bogacz A, Czerny B, Karasiewicz M, Kujawski R, Mikolajczak PL, Seremak-Mrozikiewicz A, Grzeskowiak E, Bobkiewicz-Kozlowska T. The influence of a standardized soybean extract (Glycine max) on the expression level of cytochrome P450 genes in vivo. Ginekol Pol 2010; 81: 516-520 [PMID: 20825053]
78. Yang HY, Tzeng YH, Chai CY, Hsieh AT, Chen JR, Chang LS, Yang SS. Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. Nutrition 2011; 27: 943-948 [PMID: 21333494 DOI: 10.1016/j.nut.2010.09.004]
79. Hwang YP, Choi CY, Chung YC, Jeon SS, Jeong HG. Protective effects of puerarin on carbon tetrachloride-induced hepatotoxicity. Arch Pharm Res 2007; 30: 1309-1317 [PMID: 18038910 DOI: 10.1007/BF02980272]
80. Fukunishi S, Sujishi T, Takeshita A, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K. Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Biochem Nutr 2014; 54: 39-44 [PMID: 24426189 DOI: 10.3164/jcbn.13-49]
81. Ramana KV, Fadl AA, Tammali R, Reddy AB, Chopra AK, Srivastava SK. Aldose reductase mediates the lipopolysaccharideinduced release of inflammatory mediators in RAW264.7 murine macrophages. J Biol Chem 2006; 281: 33019-33029 [PMID: 16956889 DOI: 10.1074/jbc.M603819200]
82. Shoeb M, Yadav UC, Srivastava SK, Ramana KV. Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages. Free Radic Biol Med 2011; 51: 1686-1696 [PMID: 21856412 DOI: 10.1016/j.freeradbiomed.2011.07.024]
83. Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 2001; 296: 181-187 [PMID: 11123379]
84. Zhao JH, Arao Y, Sun SJ, Kikuchi A, Kayama F. Oral administration of soy-derived genistin suppresses lipopolysaccharideinduced acute liver inflammation but does not induce thymic atrophy in the rat. Life Sci 2006; 78: 812-819 [PMID: 16257011 DOI: 10.1016/j.lfs.2005.05.104]
85. Lin X, Zhang S, Huang R, Wei L, Liang C, Chen Y, Lv S, Liang S, Wu X, Huang Q. Protective effect of genistein on lipopolysaccharide/D-galactosamine-induced hepatic failure in mice. Biol Pharm Bull 2014; 37: 625-632 [PMID: 24818258]
86. Ruetten H, Thiemermann C. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. Br J Pharmacol 1997; 122: 59-70 [PMID: 9298529 DOI: 10.1038/sj.bjp.0701345]